Skip to main content

Advertisement

SpringerLink
Log in

Changes of Bone Metabolism in Seven Patients with Gaucher Disease Treated Consecutively with Imiglucerase and Miglustat

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Bone manifestations are frequent in Gaucher disease (GD), the most prevalent lysosomal storage disorder. Currently, therapy with enzyme replacement (ERT) or substrate reduction (SRT) is available. We investigated changes of laboratory parameters associated with bone metabolism in GD patients switching from ERT to SRT. Seven GD patients consecutively treated with ERT and SRT were studied. All patients had different degrees of bone involvement. Laboratory results were acquired at the time of change from ERT to SRT (0 months) and while on SRT (6 months, 12–18 months). Markers of GD activity remained stable or showed statistically insignificant increases. Six patients had stable skeletal manifestations and reported no bone-associated symptoms. One patient presented progressive bone manifestations on magnetic resonance imaging and experienced increasing bone pain. Osteocalcin, alkaline phosphatase, and C-terminal telopeptide of collagen I were initially within the lower part of the normal range and decreased during SRT (alkaline phosphatase P = 0.0169, osteocalcin nonsignificant, C-terminal telopeptide of collagen I nonsignificant). Tartrate-resistant acid phosphatase 5b was initially normal or slightly increased, and macrophage colony-stimulating factor was within the normal lower range; both parameters remained stable. Interleukin-6 was elevated only in the patient with progressive bone disease. Macrophage inflammatory protein 1α (MIP-1α) was elevated without change after switching to SRT. MIP-1β was within the normal range, and no values were above 85 ng/mL, indicative of active skeletal disease. From a clinical and metabolic point of view, most skeletal manifestations and bone-associated laboratory parameters remain stable after switch from ERT to SRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Mehta A (2006) Epidemiology and natural history of Gaucher’s disease. Eur J Intern Med 17:S2–S5

    Article  PubMed  CAS  Google Scholar 

  2. Hollak CE, Pastores GM (2004) Type I Gaucher disease. In: Zimran A (ed) Glycolipid storage disorders. Adis Communications, Abington, pp 17–26

    Google Scholar 

  3. Wentrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75 Suppl 1:A2–A12

    Google Scholar 

  4. Germain DP (2004) Gaucher’s disease: a paradigm for interventional genetics. Clin Genet 65:77–86

    Article  PubMed  CAS  Google Scholar 

  5. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant resources. Ann Intern Med 122:33–39

    PubMed  CAS  Google Scholar 

  6. Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A (1998) Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM 91:483–488

    Article  PubMed  CAS  Google Scholar 

  7. Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher disease. Lancet 345:1474–1478

    Article  PubMed  CAS  Google Scholar 

  8. Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82:408–416

    PubMed  CAS  Google Scholar 

  9. Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wentrup RJ (2002) Bone complications in children with Gaucher disease. Br J Radiol 75 Suppl 1:A37–A44

    Google Scholar 

  10. Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, Agosti E (1994) Enzyme replacement treatment in type 1 and type 3 Gaucher´s disease. Lancet 344:1679–1682

    Article  PubMed  CAS  Google Scholar 

  11. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M (2006) Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher´s disease. Hematologica 91:703–706

    CAS  Google Scholar 

  12. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757–766

    Article  PubMed  CAS  Google Scholar 

  13. Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27:1215–1227

    Article  PubMed  CAS  Google Scholar 

  14. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71:205–211

    Article  PubMed  CAS  Google Scholar 

  15. Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Niederau C, Haussinger D, Modder U (2001) Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 30:496–503

    Article  PubMed  CAS  Google Scholar 

  16. Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, Weinreb NJ (2002) Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75(Suppl 1):A25–A36

    Google Scholar 

  17. de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, Wiersma MG, Haussinger D, Brett S, Brill N, vom Dahl S (2006) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108:850–855

    Article  Google Scholar 

  18. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner T (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 21:119–126

    Article  Google Scholar 

  19. Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores GM (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71:576–588

    Article  PubMed  CAS  Google Scholar 

  20. Pastores G, Elstein D, Hrebicek M, Zimran A (2007) Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational open-label studies. Clin Ther 29:1645–1654

    Article  PubMed  CAS  Google Scholar 

  21. Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyiel M, Ronfani L, Vidoni L, Pittis MG, Bembi B (2005) Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28:723–732

    Google Scholar 

  22. Ciana G, Martini C, Leopaldi A, Tamoro G, Katouzian F, Ronfani L, Bembi B (2003) Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72:185–189

    Article  PubMed  CAS  Google Scholar 

  23. Drugan C, Jebeleanu G, Grigorescu-Sido P, Caillaud C, Craciun AM (2002) Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 28:13–20

    Article  PubMed  CAS  Google Scholar 

  24. Fiore CE, Barone R, Pennisi P, Pavone V, Riccobene S (2002) Bone ultrasonometry, bone density, and bone turnover markers in type 1 Gaucher disease. J Bone Miner Metab 20:24–38

    Article  Google Scholar 

  25. Mehta A (2006) Clinical experience with substrate reduction therapy. Eur J Intern Med 17:S13–S15

    Article  PubMed  CAS  Google Scholar 

  26. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A (2006) Intraveneous enzyme replacement therapy: better in home or hospital? Br J Nurs 15:330–333

    PubMed  CAS  Google Scholar 

  27. Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ (2003) Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging—initial experience. Radiology 229:554–561

    Article  PubMed  Google Scholar 

  28. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. QJM 90:19–25

    PubMed  CAS  Google Scholar 

  29. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S (1999) Cytokines in Gaucher’s disease. Eur Cytokine Netw 10:205–210

    PubMed  CAS  Google Scholar 

  30. Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F (2007) Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772:788–796

    PubMed  Google Scholar 

  31. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87:7260–7264

    Article  PubMed  CAS  Google Scholar 

  32. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41:4–14

    Article  PubMed  Google Scholar 

  33. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281

    Article  PubMed  CAS  Google Scholar 

  34. Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135:317–322

    PubMed  CAS  Google Scholar 

  35. Zittermann A (2003) Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89:552–572

    Article  PubMed  CAS  Google Scholar 

  36. Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201–212

    Article  PubMed  CAS  Google Scholar 

  37. vom Dahl S, Poll L, Di Rocco M, Ciana G, Denes C, Mariani G, Maas M (2006) Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 22:1045–1064

    Article  PubMed  CAS  Google Scholar 

  38. Czartoryska B, Tylki-Szymańska A, Lugowska A (2000) Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 33:147–149

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and Endocrinology, PET Center, State Hospital Klagenfurt, St. Veiterstr. 47, 9020, Klagenfurt, Austria

    P. Mikosch

  2. Department of Internal Medicine II, State Hospital Klagenfurt, Klagenfurt, Austria

    P. Mikosch

  3. Lysosomal Storage Disorder Unit, Department of Academic Hematology, Royal Free and University College Medical School, London, UK

    M. Reed, R. Baker, A. B. Mehta & D. A. Hughes

  4. Department of Radiology, Royal Free and University College Medical School, London, UK

    B. Holloway & L. Berger

Authors
  1. P. Mikosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Reed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Holloway
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. B. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. A. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Mikosch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikosch, P., Reed, M., Baker, R. et al. Changes of Bone Metabolism in Seven Patients with Gaucher Disease Treated Consecutively with Imiglucerase and Miglustat. Calcif Tissue Int 83, 43–54 (2008). https://doi.org/10.1007/s00223-008-9143-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-008-9143-4

Keywords

Search

Navigation